愛(ài)德·塔利亞布教授接受記者專訪。 深圳特區(qū)報(bào)記者 姜鑫 攝 Prof. Aldo Tagliabue during an interview with Shenzhen Special Zone Daily. Jiang Xin

釜山Marine City和廣安大橋夜景。 Night view of Busan’s Marine City and Gwangan Bridge.

深圳新聞網(wǎng)2026年5月20日訊（深圳特區(qū)報(bào)記者 吳徐美）在深圳先進(jìn)技術(shù)研究院研究員、免疫與炎癥研究室首席科學(xué)家愛(ài)德·塔利亞布眼中，疫苗從來(lái)不是冰冷的科研產(chǎn)物，而是守護(hù)人類健康的“隱形盾牌”。深耕免疫學(xué)領(lǐng)域半個(gè)世紀(jì)、橫跨歐美亞三大洲的他，曾參與研發(fā)出人類首款重組無(wú)細(xì)胞百日咳疫苗、B型腦膜炎疫苗等成果，手握11項(xiàng)科研專利，兩度斬獲意大利科研轉(zhuǎn)化最高獎(jiǎng)，用技術(shù)為全球公共衛(wèi)生保駕護(hù)航。如今，他扎根深圳深耕疫苗研發(fā)，牽頭組建科研團(tuán)隊(duì)、推動(dòng)國(guó)際合作。談及2026年深圳APEC會(huì)議，這位來(lái)自意大利的科學(xué)家表示，“深圳不僅是盛會(huì)承辦地，這座城市本身也將成為亞太科創(chuàng)協(xié)同的核心樞紐?！?/span>

跨越半個(gè)世紀(jì)的免疫科研路

走進(jìn)塔利亞布教授的辦公室，最先映入眼簾的是墻上張貼的兩張地圖，除了一張碩大的中國(guó)地圖，一旁的深圳市地圖上，已被這位來(lái)自意大利的科學(xué)家圈出了許多深圳知名地標(biāo)，他還用手比畫了一下深圳與香港的距離：“就在河對(duì)岸，很近?！?/p>

“我?guī)缀跏桥既贿M(jìn)入免疫學(xué)領(lǐng)域的?！彼麃啿蓟貞浄Q，那是在20世紀(jì)70年代中期，免疫學(xué)正以驚人的速度發(fā)展，他抱著試試看的心態(tài)踏入這片新天地，卻從此愛(ài)上了這門科學(xué)。在塔利亞布40多年的職業(yè)生涯中，他最引以為傲的高光時(shí)刻，就是與疫苗大師里諾·拉普奧利共事的歲月?！拔覀兂晒ρ邪l(fā)了兩款重要疫苗，一是重組無(wú)細(xì)胞百日咳疫苗，這是人類歷史上第一個(gè)針對(duì)細(xì)菌性疾病的重組疫苗。二是通過(guò)‘反向疫苗學(xué)’技術(shù)研發(fā)的B型腦膜炎疫苗Bexsero?！彼锌?。

“疫苗不是大生意，卻是救命的事業(yè)。”塔利亞布強(qiáng)調(diào)，“相比需要終身服藥的慢性病藥物，疫苗可能只需幾十美元，但它能徹底改變一個(gè)地區(qū)的疾病負(fù)擔(dān)?！?/p>

扎根深圳開(kāi)啟疫苗研發(fā)新篇

塔利亞布與中國(guó)的緣分，最早可追溯至2006年。彼時(shí)他任職韓國(guó)首爾國(guó)際疫苗研究所研發(fā)主任，牽頭協(xié)調(diào)中、韓、德、意四國(guó)科學(xué)家組建項(xiàng)目團(tuán)隊(duì)，合力攻關(guān)SARS疫苗研發(fā)。項(xiàng)目年度會(huì)議在上海舉辦，這也是他第一次踏上中國(guó)土地。

此后20年間，他始終與中國(guó)科研界保持密切學(xué)術(shù)交流與項(xiàng)目合作。2019年，曾共事的中方學(xué)者向他發(fā)出邀約，邀請(qǐng)其加盟中國(guó)科學(xué)院深圳先進(jìn)技術(shù)研究院?！拔艺J(rèn)為這是在中國(guó)科研沃土開(kāi)啟全新事業(yè)的絕佳契機(jī)?！彼麃啿颊f(shuō)，他與同為科研工作者的妻子商議后，下定決心舉家奔赴深圳，籌建專注于感染免疫與疫苗研發(fā)的科研團(tuán)隊(duì)。

“為了讓我們提前了解深圳這座城市，我女兒還送了一本《深圳試驗(yàn)：中國(guó)速生城市的故事》給我們。從這本書里，我知曉并回顧了深圳在過(guò)去40多年間如何崛起為一座千萬(wàn)級(jí)人口的現(xiàn)代化國(guó)際城市。”塔利亞布表示。

記者留意到，辦公室醒目位置擺放著“炎癥與疫苗研究室”牌匾，這是塔利亞布加盟中國(guó)科學(xué)院深圳先進(jìn)技術(shù)研究院后，牽頭組建聚焦新型免疫治療藥物與創(chuàng)新疫苗研發(fā)的實(shí)驗(yàn)室。同時(shí)，作為先進(jìn)院炎癥與疫苗研究室首席科學(xué)家，他代表深圳先進(jìn)院建立并推動(dòng)多個(gè)國(guó)際合作項(xiàng)目的落地，包括參與中國(guó)科學(xué)院“一帶一路”國(guó)際合作項(xiàng)目、比爾及梅琳達(dá)·蓋茨基金會(huì)項(xiàng)目、參與國(guó)家自然科學(xué)基金國(guó)際合作研究項(xiàng)目、聯(lián)合意大利錫耶納生命科學(xué)基金會(huì)聯(lián)合攻關(guān)人體抗新冠病毒免疫力效果研究等，并致力于推動(dòng)廣泛的中歐合作及建立中意聯(lián)合實(shí)驗(yàn)室等。

如今，塔利亞布教授培養(yǎng)出數(shù)十名中國(guó)人才并且以中國(guó)為中心開(kāi)展了10余次人才與技術(shù)交流活動(dòng)，組建了覆蓋免疫學(xué)、疫苗學(xué)、納米醫(yī)學(xué)等研究方向的20余人科研團(tuán)隊(duì)，助力推動(dòng)中國(guó)疫苗產(chǎn)業(yè)加速國(guó)際化發(fā)展。

深圳將成為APEC會(huì)議關(guān)注焦點(diǎn)

作為一位親身經(jīng)歷過(guò)多次跨國(guó)合作的科學(xué)家，塔利亞布對(duì)2026年在深圳舉辦的APEC會(huì)議寄予厚望：“APEC匯聚21個(gè)經(jīng)濟(jì)體，在組織架構(gòu)與協(xié)作模式上，與歐盟有著相似之處，即必須匯聚各方力量，整合資金、技術(shù)等資源，才能在科技創(chuàng)新領(lǐng)域形成合力、協(xié)同攻關(guān)。”

“事實(shí)上，深圳不僅是此次舉辦APEC的東道主，城市本身，也將成為APEC會(huì)議關(guān)注的焦點(diǎn)之一。”塔利亞布說(shuō)，作為粵港澳大灣區(qū)核心引擎城市，深圳串聯(lián)起港澳與內(nèi)地創(chuàng)新資源，是全球數(shù)據(jù)治理、人工智能、生物技術(shù)融合發(fā)展的重要樞紐。

從米蘭到錫耶納，從首爾到深圳，這位意大利科學(xué)家的科研人生橫跨大陸、穿越時(shí)間。而在他的辦公室里，那些密密麻麻標(biāo)注的地圖、手繪賀卡，正無(wú)聲地講述著一個(gè)關(guān)于熱愛(ài)與選擇的故事，正如他自己所言：“當(dāng)你有一個(gè)夢(mèng)想，你就必須去實(shí)現(xiàn)。”

Aldo Tagliabue, a researcher at Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences and chief scientist of the Laboratory Inflammation and Vaccines:

Shenzhen: The beating heart of Asia-Pacific’s tech synergy

■ Wu Xumei, Shenzhen Special Zone Daily

To Italian immunologist Aldo Tagliabue, vaccines are never mere “cold scientific products.” Instead, he views them as “invisible shields” safeguarding human life.

Now a researcher at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences and chief scientist of the Laboratory of Inflammation and Vaccines, Tagliabue brings half a century of expertise spanning Europe, the Americas, and Asia to China’s “Silicon Valley.”

With 11 scientific patents and two of Italy’s highest awards for scientific technology transfer, Tagliabue is perhaps best known for his role in developing the world’s first recombinant vaccine against Bordetella pertussis (whooping cough) and the Meningococcus B vaccine. Today, his focus is rooted in Shenzhen, where he leads a diverse scientific team and fosters high-level international collaboration.

“Shenzhen is more than just a host city,” Tagliabue said, referring to the upcoming 2026 APEC meeting. “The city itself has become a core agenda item for Asia-Pacific technological collaboration.”

Tagliabue’s office offers a glimpse into his dual world. On the wall, a large map of China hangs alongside a map of Shenzhen, where he has circled dozens of local landmarks. Gesturing toward the border, he noted, “Hong Kong is just across the river — it is very close.”

His entry into the field of immunology in the mid-1970s was almost serendipitous, he recalled. At the time, the field was evolving at an astonishing pace. He took a chance on the burgeoning science and never looked back.

The peak of his 40-year career came while working alongside the renowned Italian vaccine pioneer Rino Rappuoli. Together, they developed the recombinant acellular pertussis vaccine — the first of its kind against a bacterial disease — and Bexsero, a meningitis B vaccine created using groundbreaking “reverse vaccinology.”

“Vaccines are not a big profit-making business; they are a life-saving cause,” Tagliabue said. “Unlike chronic disease drugs that require lifelong use, a vaccine costing a few dozen dollars can alleviate the entire disease burden of a region.”

Tagliabue’s relationship with China began in 2006. While serving as the R&D director at the International Vaccine Institute in Seoul, South Korea, he coordinated a multinational team from China, South Korea, Germany, and Italy to develop a SARS vaccine. He first visited China in 2006 for the project’s annual meeting in Shanghai.

In 2019, a long-time Chinese colleague invited him to join SIAT. “I saw this as a perfect opportunity to start a new chapter in China’s fertile scientific ground,” he said. After consulting his wife — also a researcher — the couple relocated to Shenzhen to establish a research team dedicated to infection immunology and vaccine development.

To prepare for the move, his daughter gave him a book titled “The Shenzhen Experiment: The Story of China’s Instant City. ” “From that book, I learned how Shenzhen transformed into a modern international metropolis of over 10 million people in just 40 years,” he said.

At SIAT, Tagliabue led the establishment of the Laboratory of Inflammation and Vaccines. He represents the institute in several major international initiatives, including Bill & Melinda Gates Foundation ventures and joint research with Italy’s Fondazione BioSciences on COVID-19 immune responses. He is also working to expand China-Europe ties and pave the way for a new Sino-Italian joint lab.

To date, Tagliabue has mentored dozens of Chinese researchers and built a 20-person team specializing in immunology, vaccinology, and nanomedicine.

Looking ahead to the 2026 APEC meeting, Tagliabue draws a parallel between the 21-member bloc and the European Union. “APEC mirrors the EU in its reliance on collective strength,” he noted. “To achieve scientific breakthroughs, we must pool our financial and technical resources, forging a unified force for innovation.”

“Beyond being the host city, Shenzhen itself will be at the heart of the Asia-Pacific's tech innovation agenda. As a core engine of the Guangdong-Hong Kong-Macao Greater Bay Area, the city is an essential hub for the integration of global data governance, AI, and biotechnology.”

From Milan to Siena, and Seoul to Shenzhen, Tagliabue’s career has bridged continents. In his office, the annotated maps and hand-drawn cards serve as a testament to his journey.

“When you have a dream,” he said, “you must go and achieve it.”

(Translated by Li Jing)

回眸APEC

APEC Through the Years

第十三站：韓國(guó)釜山

亞太經(jīng)濟(jì)合作組織領(lǐng)導(dǎo)人第13次非正式會(huì)議于2005年11月18日在韓國(guó)釜山舉行，會(huì)議完成了對(duì)茂物目標(biāo)的中期審評(píng)，制定了旨在實(shí)現(xiàn)茂物目標(biāo)的“釜山路線圖”。

釜山位于韓國(guó)東南端，是韓國(guó)最大的港口和第二大城市，為韓國(guó)6個(gè)廣域市之一，也是國(guó)際旅游城市。釜山是韓國(guó)工商、金融和信息中心，為通向世界的歐亞大陸樞紐城市，釜山鎮(zhèn)海經(jīng)濟(jì)自由區(qū)的建立進(jìn)一步鞏固了該地貿(mào)易中心和金融中心的地位。

13th Stop:

Busan, South Korea

The 13th APEC Economic Leaders’ Meeting convened in Busan, South Korea, on Nov. 18, 2005. The summit completed a midterm review of the Bogor Goals and adopted the “Busan Roadmap” to accelerate free and open trade.

Perched on southeastern tip of the Korean Peninsula, Busan is South Korea’s largest port and second-largest city. A gateway to the world and a vital Eurasian hub, the city excels in industry, finance, and information technology. The Busan-Jinhae Free Economic Zone has further cemented its reputation as a global trade and tourism powerhouse.

APEC風(fēng)物志

APEC Cultural Highlights

韓定食，又稱韓國(guó)式客飯、韓式套餐，是韓國(guó)傳統(tǒng)飲食中較正式的宴席形式。標(biāo)準(zhǔn)配置包含米飯、湯品、泡菜及小瓷鍋燉湯，主菜常見(jiàn)九折板（小麥煎餅包肉類蔬菜）與神仙爐（燉煮火鍋），輔以煎餅類、生魚片等。烹飪方式涵蓋蒸、烤、燙、拌等，除泡菜外不采用辣椒粉調(diào)味。菜肴按3至12碟規(guī)格陳列，包含前菜、主食、副食及餐后甜點(diǎn)。

Hanjeongsik, the quintessential Korean formal set meal, is a masterpiece of traditional banquet-style dining. It centers on rice, soup, kimchi, and a savory hot pot stew. Highlights often include Gujeolpan (an elegant platter of nine delicacies wrapped in thin wheat pancakes) and Sinseollo (a royal hot pot). Cooking relies on steaming, grilling, and blanching; no chili powder is used except in kimchi. A full course ranges from three to 12 side dishes, flowing from appetizers to main courses and ending with traditional desserts.